Clinical Trials
36 trialsPaclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer
National Cancer Institute (NCI)
Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer
University of Maryland, Baltimore
Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer
Virginia Commonwealth University
Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Bryostatin 1 and Cisplatin in Treating Patients With Metastatic or Unresectable Stomach Cancer
National Cancer Institute (NCI)
Bryostatin 1 Plus Cladribine in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
Barbara Ann Karmanos Cancer Institute
Bryostatin 1 Plus Gemcitabine in Treating Patients With Advanced Cancer
Barbara Ann Karmanos Cancer Institute
Bryostatin 1 in Treating Patients With Recurrent or Refractory Hodgkin's Disease
Barbara Ann Karmanos Cancer Institute
Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Cisplatin Plus Bryostatin 1 in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Bryostatin-1 Plus Cisplatin in Treating Patients With Recurrent or Advanced Cancer of the Cervix
National Cancer Institute (NCI)
Bryostatin 1 in Treating Patients With Ovarian Epithelial Cancer
National Cancer Institute (NCI)
Bryostatin 1 In Treating Patients With Progressive Kidney Cancer
National Cancer Institute (NCI)
Bryostatin 1 Plus Paclitaxel and Cisplatin in Treating Patients With Advanced Solid Tumors
Memorial Sloan Kettering Cancer Center
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Memorial Sloan Kettering Cancer Center
Bryostatin 1 Plus Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer or Stomach Cancer
National Cancer Institute (NCI)
Bryostatin 1 in Treating Patients With Stage IV Breast Cancer
University of Colorado, Denver
Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors
National Cancer Institute (NCI)
Bryostatin 1 in Treating Patients With Relapsed Multiple Myeloma
Barbara Ann Karmanos Cancer Institute
Bryostatin 1 in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Barbara Ann Karmanos Cancer Institute
Bryostatin 1 in Treating Patients With Myelodysplastic Syndrome
Barbara Ann Karmanos Cancer Institute
Bryostatin 1 in Treating Patients With Metastatic Colorectal Cancer
Barbara Ann Karmanos Cancer Institute
Bryostatin 1 Plus Paclitaxel in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer
University of Chicago
Bryostatin 1 in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Bryostatin-1 in Treating Patients With Recurrent Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Bryostatin 1 Plus Vincristine in Treating Patients With Recurrent or Refractory HIV-Related Lymphoma
National Cancer Institute (NCI)
Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer
National Cancer Institute (NCI)
Bryostatin and Vincristine in B-Cell Malignancies
National Cancer Institute (NCI)
Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell Transplantation
National Cancer Institute (NCI)
Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer
National Cancer Institute (NCI)
Bryostatin 1 Plus Cisplatin in Treating Patients With Metastatic or Unresectable Cancer
NYU Langone Health
A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Dana-Farber Cancer Institute
Bryostatin 1 and Cytarabine in Treating Patients With Relapsed Acute Myelogenous Leukemia
Virginia Commonwealth University
Bryostatin + Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia or Relapsed Indolent Non-Hodgkin's Lymphoma
Virginia Commonwealth University
Bryostatin 1 and High Dose Cytarabine in Treating Patients With Refractory or Relapsed Leukemia or Lymphoma
Virginia Commonwealth University